

1 **Serum Vitamin D levels are associated with increased COVID-19**
2 **severity and mortality independent of visceral adiposity**

3 Pablo Esteban Vanegas-Cedillo^{1,2}, Omar Yaxmehen Bello-Chavolla^{1,3}, Natalia Ramírez-
4 Pedraza⁴, Bethsabel Rodríguez Encinas², Carolina Isabel Pérez Carrión², María Isabel
5 Jasso Ávila², Jorge Carlos Valladares García², Diana Hernández-Juárez², Arsenio Vargas-
6 Vázquez, MD^{1,4}, Neftali Eduardo Antonio-Villa^{1,4}, Monica Chapa-Ibarguengoitia⁵, Alfredo
7 Ponce de Leon⁶, José Sifuentes-Osornio^{7,8}, Carlos A. Aguilar-Salinas^{1,8,9}, Roopa Mehta^{1,2*}

8
9 ¹Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
10 Médicas y Nutrición Salvador Zubirán (INCMNSZ). ²Department of Endocrinology and
11 Metabolism, INCMNSZ, ³Research Division, Instituto Nacional de Geriatria. ⁴MD/PhD
12 (PECEM) program, Faculty of Medicine, National Autonomous University of Mexico.
13 ⁵Department of Radiology, INCMNSZ, ⁶Department of Infectious Diseases, INCMNSZ,
14 ⁷Internal Medicine Division, INCMNSZ ⁸Instituto Tecnológico y de Estudios Superiores de
15 Monterrey Tec Salud, ⁹Division of Nutrition, INCMNSZ.

16 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

17 *Correspondence: Roopa Mehta

18 Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
19 Médicas y Nutrición Salvador Zubirán/ Department of Endocrinology and Metabolism,
20 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

21 Tel +52 (55), 54 87 09 00, 2405. Email: roopamehta@yahoo.com

22 3,105 text words; 38 references; 4 tables; 3 figures.

23 **Abstract:** 230 words

24 **Running headline:** Vitamin D, adverse COVID-19 outcomes and adiposity

25 **ABSTRACT (229 WORDS)**

26 **INTRODUCTION:** Coronavirus disease (COVID-19) is a global pandemic. Vitamin D (25-
27 OHD) deficiency has been associated with susceptibility to infectious disease. In this
28 study, the association between COVID-19 outcomes and 25-OHD levels in patients
29 attending a COVID-19 reference center in Mexico City are examined.

30 **METHODS:** Consecutive patients with confirmed COVID-19 were evaluated. All patients
31 underwent clinical evaluation (including outcomes), laboratory measurements (including
32 25-OHD) and a thoracic computerized tomography (including the measurement of
33 epicardial fat thickness). Low vitamin D was defined as levels $<20\text{ng/mL}$ ($<50\text{nmol/L}$) and
34 severely low (or deficient) 25-OHD as a level $\leq 12\text{ng/mL}$ ($<30\text{nmol/L}$)

35 **RESULTS:** Of the 551 patients included, low 25-OHD levels were present in 45.6% and
36 severely low levels in 10.9%. Severely low 25-OHD levels were associated with mortality
37 (HR 2.11, 95%CI 1.24-3.58, $p=0.006$) but not with critical COVID-19 (OR 0.97, 95%CI
38 0.94-0.99, $p=0.042$), adjusted for age, sex, body-mass index and epicardial fat. Using
39 model-based causal mediation analyses the increased risk of COVID-19 mortality
40 conferred by 25-OHD levels was partly mediated by its effect on D-dimer and cardiac
41 ultrasensitive troponins. Notably, increased risk of COVID-19 mortality conferred by low
42 vitamin D levels was independent of BMI and epicardial fat.

43 **CONCLUSION:** Vitamin D deficiency ($\leq 12\text{ng/mL}$ or $<30\text{nmol/L}$), is independently
44 associated with COVID-19 mortality after adjustment for visceral fat (epicardial fat
45 thickness). Low 25-OHD may contribute to a pro-inflammatory and pro-thrombotic state,
46 increasing the risk for adverse COVID-19 outcomes.

47 **Keywords:** Vitamin D, COVID-19, SARS-CoV-2, Adiposity, Severe disease

48 INTRODUCTION

49 Coronavirus Disease (COVID-19), caused by the novel coronavirus severe acute
50 respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. SARS-CoV-2
51 spreads primarily by close contact with respiratory droplets from infected individuals and
52 contaminated surfaces (1-3). SARS-CoV-2 infects cells using the angiotensin converting
53 enzyme-2 (ACE-2) receptor; infection can produce an interstitial pneumonia that may
54 progress to acute respiratory distress syndrome (ARDS) and death (4-6).

55 Vitamin D (25-OHD) is a steroid hormone involved in essential physiological roles
56 including preserving bone integrity, immunomodulation by stimulating innate immunity and
57 tempering adaptive immunity, infectious disease prevention and cardiovascular health (7-
58 9). It also acts on the renin angiotensin aldosterone (RAAS) system, inhibiting the
59 angiotensin converting enzyme (ACE, 6). Several factors are known to influence vitamin D
60 levels; lower levels are associated with ethnicity, variation in sun exposure due to higher
61 latitudes, season, time of day, clothing, sunscreen use and skin pigmentation, age, lower
62 sun exposure, obesity and chronic illnesses (10). The presence of obesity results in
63 decreased bioavailability of vitamin D, which is probably related to sequestration into
64 adipose tissue. Furthermore, higher visceral fat content has been shown to be related to a
65 higher incidence of vitamin D deficiency (11).

66 Low levels of 25-OHD have been associated with increased susceptibility to infectious
67 disease, particularly respiratory tract infections (12-14). Several studies have explored the
68 relationship between COVID-19 and vitamin D levels (15-18); however, concerns
69 regarding residual confounding and the lack of mechanistic interpretations for the
70 association of low 25-OHD levels with adverse COVID-19 outcomes requires further
71 studies. Obesity and ethnicity are important risk factors for severe disease, and are also
72 known to modulate vitamin D levels. This may be particularly relevant in Mexico, where

73 high rates of diabetes and obesity have been associated with an increased risk of severe
74 COVID-19 (19). In this study, the association between COVID-19 outcomes and 25-OHD
75 levels in patients attending a COVID-19 reference center in Mexico City is evaluated. We
76 aim to identify determinants of 25-OHD levels in COVID-19 patients and develop causal-
77 mediation models to propose mechanisms by which Vitamin D may lead to increased
78 COVID-19 mortality.

79 **METHODS**

80 *Study population*

81 This study included consecutive patients evaluated at the Instituto Nacional de Ciencias
82 Médicas y Nutrición Salvador Zubirán, a COVID-19 reference center in Mexico City
83 between 17th March and 31st May 2020. Subjects were initially assessed at triage and
84 required either ambulatory or in-hospital care for COVID-19 (confirmed with computerized
85 tomography (CT) and/or via RT-qPCR test from nasopharyngeal swabs. All patients had
86 moderate to severe disease as defined by National Institute of Health criteria (*Moderate*
87 *Illness*: Evidence of lower respiratory disease during clinical assessment or imaging and
88 who have saturation of oxygen (SpO₂) ≥94% on air. *Severe Illness*: SpO₂ <94% on air, a
89 ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FiO₂) <300
90 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%). Subjects
91 underwent a chest CT, and a radiologist determined the degree of pulmonary parenchymal
92 disease and assessed epicardial fat thickness as a proxy for visceral fat. In addition, a
93 medical history, anthropometric measurements and laboratory tests were obtained,
94 including 25 hydroxy-vitamin D (25(OH)-D). The electronic files of each patient were
95 reviewed to document the outcomes during hospitalization. All proceedings were approved
96 by the research and ethics committee of the INCMNZ (Ref 3383) and informed consent
97 was waived due to the nature of the study.

98 *Laboratory and clinical measurements*

99 Clinical variables and laboratory measures were obtained at the time of initial evaluation.
100 Physical examination included: weight, height, body mass index (BMI, calculated as weight
101 in kilograms divided by squared height in meters), pulse oximeter saturation (SpO₂),
102 respiratory rate (RR), temperature and arterial blood pressure (BP). Laboratory
103 measurements included: full blood count and chemistry panel including liver function tests,
104 C-reactive protein (CRP), fibrinogen, D-dimer, ferritin, troponin I (TPNI), erythrocyte
105 sedimentation rate (ESR) and procalcitonin levels. The blood samples were processed in
106 the central laboratory of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador
107 Zubirán, Vitamin D (25-hydroxivitamin D) was measured by chemiluminescence using the
108 Abbott Architect I2000 equipment. Low levels of vitamin D were defined as <20ng/mL (<50
109 nmol/L) and severely low (or deficiency) as a level <12ng/mL (<30nmol/L) (6-9).

110 *Epicardial fat measurements*

111 All patients underwent unenhanced CT scans including low-dose CT and two ultra-low-
112 dose CT protocols with commonly reported imaging features of COVID-19 pneumonia.
113 The thoracic CT was performed using a 64-slice scanner (GE MEDICAL SYSTEMS
114 Revolution EVO). Epicardial adipose tissue (EAT) thickness was measured at 3 points
115 (right atrioventricular fossa, left atrioventricular fossa, and anterior interventricular fossa) in
116 the reformatted 4-chamber view using the multiplanar reconstruction (MPR) tool on the
117 workstation (20, 21, 22). The maximum thickness of the EAT was determined from the
118 surface of the myocardium to the pericardium (measured perpendicular to the
119 pericardium). The measurements were made on 2 different occasions, obtaining a total of
120 6 measurements; the average of them was used for all statistical analyses. Pericardial
121 adipose tissue (PAT) was quantified with the volume measurement tool with the
122 Carestream system of the workstation. The thickness of the thoracic subcutaneous

123 adipose tissue (TscAT) was measured from the anterior border of the sternum to the skin,
124 at the level of the mitral valve in the axial plane of the tomography. The 80th gender-
125 specific percentile of EAT thickness was obtained and used as the threshold to define
126 increased EAT thickness. In addition, chest CT findings were recorded and used to
127 evaluate severity of COVID infection.

128 *COVID-19 outcomes*

129 Outcomes included mortality and critical disease (defined as the combination of mortality
130 and need for mechanical ventilation /intubation). For time-to-event analyses, time from
131 self-reported symptom onset prior to evaluation until last follow-up (censoring) or death,
132 whichever occurred first was estimated.

133 *Statistical analyses*

134 Cases with low and severely low vitamin D levels were analyzed using Student's t-test or
135 Mann-Whitney U according to the variable distribution (parametric or non-parametric) for
136 continuous variables. The chi-squared test was applied for categorical variables.
137 Logarithmic, squared root and cubic root transformations were carried out to ensure
138 variable symmetry prior to modeling. All statistical analyses were conducted using R 4.0.2.

139 *Prediction of mortality and severe COVID-19*

140 Cox proportional risk regression analyses was used to investigate the association of
141 vitamin D with mortality related to COVID-19. Univariate models and fully adjusted models
142 were generated which included the following covariates: age, gender, BMI, C-reactive
143 protein, D-dimer, ultrasensitive cardiac troponin, epicardial fat, T2D, CKD and oxygen
144 saturation levels. An interaction effect was explored with BMI or BMI categories to rule out
145 the differential impact of vitamin D adjusted for BMI. Model diagnostics were done using
146 Schoenfeld residuals. Finally, the association of vitamin D with requirement for mechanical

147 ventilation or the composite of critical COVID-19 was explored using logistic regression
148 analyses adjusted for the aforementioned covariates.

149 *Predictors of vitamin D levels*

150 Linear regression analyses were fitted to identify predictors of log-transformed vitamin D
151 levels in patients with COVID-19, and model selection was carried out using minimization
152 of the Bayesian Information Criterion (BIC). Logistic regression models were also fitted
153 using a dummy variable which defined low and severely low vitamin D to identify predictors
154 for these categories and again model selection was conducted using BIC. Finally, model
155 diagnostics for linear regression were conducted using residual analyses and the Hosmer-
156 Lemeshow test for logistic regression analyses.

157 *Causal mediation models*

158 Finally, to explore whether variables which are influenced by Vitamin D levels may act as a
159 mediator of the risk conferred by Vitamin D on COVID-19 severity, model-based causal
160 mediation analyses were developed: D-dimer and ultrasensitive cardiac troponins were
161 proposed as mediators of the effect of Vitamin D on COVID-19 mortality. All mediation
162 analyses were performed using the mediation R package; to permit inference to obtain a
163 95% confidence interval using bias-corrected accelerated non-parametric bootstrap. To
164 demonstrate the sequential ignorability assumption, a sensitivity analysis was run to
165 demonstrate residual confounding by varying the correlation between the residuals of both
166 the outcome and the moderator models. Statistical analyses were performed using R
167 software version 4.0.3. A p value <0.05 was considered statistically significant

168 **RESULTS**

169 *Study population*

170 This study included 551 patients with confirmed COVID-19 (with compatible computerized
171 tomography findings and/or positive RT-qPCR test from nasopharyngeal swabs) and

172 vitamin D measurements. The mean age of participants was 51.92 ± 13.74 years, with a
173 male predominance ($n=355$, 64.4%), and a mean BMI of 30.05 ± 5.72 . Median follow-up
174 was 15.0 days (IQR 10.0-20.0) and 445 patients required hospitalization (81.1%). Overall,
175 93 patients received invasive mechanical ventilation (16.88%) and 116 in-hospital deaths
176 (21.1%) were recorded. Type 2 diabetes (T2D) was present in 146 patients (26.9%), 219
177 patients had obesity (42.7%) and 217 were overweight (42.4%). Mean vitamin D levels
178 were 21.78 ± 9.01 and vitamin D levels below 20ng/mL were present in 251 subjects
179 (45.6%) (**Table 1**). Extremely low vitamin D levels (≤ 12 ng/mL) were observed in 59
180 patients (10.7%) (**Table 1 supplementary material**).

181 *Determinants of Vitamin D levels amongst patients with COVID-19*

182 The pathophysiological adaptations to COVID-19 may be predictive of low vitamin D
183 levels. To this end, determinants of low vitamin D in COVID-19 were sought in an attempt
184 to develop a mechanistic explanatory model for this relationship. Subjects with low vitamin
185 D levels (< 20 mmg/dl) were more likely to be female, have type 2 diabetes, higher HbA1c,
186 D-dimer and ferritin levels and lower oxygen saturation, albumin and C-reactive protein.
187 Using linear regression, a lower log-transformed vitamin D level was independently
188 associated with female gender, higher log-transformed ultrasensitive cardiac troponin,
189 higher log-transformed D-dimer, higher log-transformed epicardial fat area, and lower C-
190 reactive protein levels (**Table 2**). When exploring a model to detect low vitamin D levels,
191 there was a significantly higher odds for log-transformed D-dimer levels (OR 1.31, 95%CI
192 1.06-1.63); lower odds were associated with male gender (OR 0.45, 95%CI 0.31-0.65),
193 higher oxygen saturation levels (OR 0.98, 95%CI 0.97-0.99) and higher C-reactive protein
194 values (OR 0.75, 95%CI 0.61-0.92), adjusted for age, and log-transformed epicardial fat.
195 There was no association between days from symptom onset and vitamin D levels at
196 admission.

197 *Vitamin D levels and COVID-19 mortality*

198 Overall, vitamin D levels were significantly lower when comparing non-fatal to fatal COVID-
199 19 cases (22.41 ± 9.34 vs. 19.44 ± 67.19 , $p < 0.001$). When assessing risk related to the
200 association between mortality and vitamin D levels using Cox regression, a 1-unit increase
201 in vitamin D levels was associated with a decreased risk of COVID-19 mortality.
202 Interestingly, when stratifying cases according to gender, the difference in vitamin D levels
203 between fatal and non-fatal cases was greater in women compared to men and lower in
204 cases with obesity (**Figure 1**). When the mortality models were adjusted for age, gender,
205 BMI, and C-reactive protein, CKD and T2D the observed association between vitamin D
206 levels and a decrease in COVID-19 mortality persisted (**Table 3**). There was no significant
207 interaction with BMI, (as a continuous variable or categorized) in normal weight,
208 overweight and obese with vitamin D levels. Using post-estimation simulation to predict
209 risk associated with changes in vitamin D levels using the simPH R package, there was a
210 steady decrease in risk attributable to increasing vitamin D concentrations using vitamin D
211 $< 20 \text{ ng/mL}$ and $\leq 12 \text{ ng/mL}$ as thresholds (**Figure 2**).

212 *Vitamin D and critical COVID-19*

213 When assessing the impact of vitamin D on the risk of invasive mechanical ventilation
214 there was no significant association even after adjustment for age, gender, BMI, C-reactive
215 protein, CKD or T2D status (OR 0.986, 95%CI 0.957-1.015, $p = 0.366$). However, when
216 assessing the composite of critical COVID-19 using logistic regression models, lower
217 vitamin D levels were associated with critical COVID-19 (OR 0.97, 95%CI 0.94-0.99,
218 $p = 0.042$, adjusting by age, gender, BMI, C-reactive protein, D-dimer, CKD, SpO₂ or T2D
219 status).

220 *Causal mediation models*

221 Finally, model-based causal mediation models were developed to assess whether the
222 effect of vitamin D (E) on increased mortality risk (Y) was mediated through changes in
223 variables identified in **Table 2** (M), adjusted for age, gender, BMI and epicardial fat. The
224 direct effect of vitamin D on increased mortality risk was significant ($\Delta_{E \rightarrow Y}$ -0.144, 95%CI -
225 0.069, -0.010) and the indirect effect of vitamin D, mediated by increase D-dimer levels
226 ($\Delta_{E \rightarrow MY}$ -0.035, 95%CI -0.164, -0.010), represented 19.3% (95%CI 9.5-77.0%) of the
227 overall association of vitamin D on mortality. A similar scenario was observed for cardiac
228 troponins, whereby both the direct effect of vitamin D on mortality ($\Delta_{E \rightarrow Y}$ -0.133, 95%CI -
229 0.150, -0.020) and the indirect effect mediated by ultrasensitive cardiac troponins ($\Delta_{E \rightarrow MY}$ -
230 0.047, 95%CI -0.085, -0.020), were significant and represented 26.2% (95%CI 14.9-
231 73.0%) of the overall effect of vitamin D on mortality. Notably, there were no significant
232 causal mediation models for either BMI or epicardial fat, here there was only a direct effect
233 on mortality, independent of vitamin D levels.

234 **DISCUSSION**

235 In this study, the association between vitamin D levels and severity of COVID-19 was
236 explored in a Mexican population. Severely low levels of vitamin D (deficiency) showed a
237 clear association with mortality, even after adjusting for confounders, including epicardial
238 fat as a proxy of visceral fat and BMI. A vitamin D level <20ng/mL (<50nmol/L), showed a
239 strong negative predictive value, suggesting that when levels are adequate, the probability
240 of mortality is low. Furthermore, the increased risk of mortality from COVID-19 was partly
241 mediated by the effect of vitamin D on markers of disease severity, such as D-dimer and
242 ultrasensitive cardiac troponins, independent of BMI and epicardial fat (these showed
243 effects on COVID-19 mortality independent of vitamin D levels). This suggests that vitamin
244 D may be a marker of an impaired response to infection within the pulmonary epithelium,
245 in particular in those with severe deficiency (23).

246 Several studies have explored the relationship between COVID-19 and vitamin D levels
247 (15-17, 24). These include those examining vitamin D levels and risk of infection and those
248 examining an association with severity of COVID-19. Higher levels of IL-6 were observed
249 in the vitamin D deficient group suggesting a greater inflammatory response in these
250 patients (18). A recent systematic review and meta-analysis reported that vitamin D
251 deficiency was not associated with increased risk of infection, but severe cases presented
252 with greater vitamin D deficiency compared with mild cases. Vitamin D deficiency has
253 been associated to increased hospitalization and mortality risk from COVID-19 (19).

254 Physiological mechanisms by which vitamin D exerts a protective function include
255 enhanced innate immunity including augmentation of physical barriers to infection and
256 optimization of adaptive immunity (25). Adequate vitamin D levels favor protective tissue
257 maintenance, preserving tight, gap and adherens junctions, all of which are disturbed by
258 viruses (26). Calcitriol (1,25 OH D) induces production of cathelicidins, LL-37 and beta-
259 defensins, proteins associated with viral surface disruption and reduced viral replication
260 rates, lower pro-inflammatory cytokine (e.g. tumor necrosis factor alpha, interleukin-6)
261 accumulation in target tissues such as the lungs and increased anti-inflammatory cytokine
262 concentrations that defend against viral infections (27). In addition, vitamin D enhances
263 macrophage phagocytosis and efferocytosis (allowing removal of cellular debris preventing
264 further inflammation), and regulation of the macrophage oxidative burst (eliciting a more
265 potent and efficient oxidative surge) (24).

266 Vitamin D also has a modulatory effect on the inflammatory response caused by COVID-
267 19. It curbs adaptive immunity by inhibiting B cell proliferation, differentiation and
268 production of antibodies and plays a role in regulation the T cell phenotype (28). Vitamin D
269 suppresses helper T cells (Th)1 proliferation, thus decreasing the synthesis of cytokines
270 such as interferon-gamma, interleukin-2 and interleukin-10 (6) (27, 29) This reduction in

271 cytokines, suppresses antigen presentation on dendritic cells and diminishes T lymphocyte
272 recruitment and proliferation. Thus, there is a shift in the adaptive immune response from
273 Th1 to a more regulatory Th2 response, characterized by an increase in expression of Th2
274 associated cytokines (IL-4, IL-10) (30, 31). This may attenuate the quantity of pro-
275 inflammatory cytokines that are associated with severe infection (32) In addition, vitamin D
276 induces ACE 2 expression, and suppresses the angiotensin-renin system, thus reducing
277 levels of proinflammatory angiotensin II. Hence, vitamin D deficiency, could potentiate the
278 cytokine storm perpetuating a pro-inflammatory state and worsening pulmonary outcomes
279 (33). Finally, thrombotic complications are common in such patients; vitamin D is also
280 involved in the regulation of thrombotic pathways (29). In our study, low vitamin D levels in
281 COVID-19 patients were related to inflammatory, pro-thrombotic and metabolic markers of
282 severity, confirming observations from previous studies.

283 Adverse COVID-19 outcomes have been linked to the ethnic origin of the population under
284 study; this has also been associated with the presence of vitamin D deficiency. Asians,
285 African Americans, and ethnic minorities are at an increased risk of mortality from COVID-
286 19 (34). This may partly be due to a decrease in the production of vitamin D dependent on
287 UV rays. This is related to the skin levels of melanin present in these populations and on
288 the unequal distribution of poverty and cardiometabolic disease rates across such
289 ethnicities. This finding is relevant and may explain lower vitamin D levels and severity of
290 COVID-19 in México in a previous study (35). Previous reports in similar populations,
291 including Hispanics, have shown higher risk of SARS-CoV-2 infection, compared to
292 Caucasian population (36).

293 Currently, routine vitamin D supplementation in hospitalized patients with COVID-19 is not
294 recommended (37). A recent pilot study showed that administration of a high dose of
295 calcifediol or 25-hydroxyvitamin D, significantly reduced the need for intensive care in

296 hospitalized patients (38). The authors speculate that calcifediol may reduce severity of
297 the disease. Ideally, additional large randomized controlled trials are needed to properly
298 assess this claim and whether vitamin D supplementation can significantly impact
299 population risk.

300 This study has certain strengths and limitations. It included a large number of patients with
301 heterogenous risk profiles in whom a variety of disease severity parameters were
302 measured. In addition, a series of statistical tests were carried out to ensure minimal
303 possibility of residual confounding. Nevertheless, some limitations must be acknowledged
304 in order to properly interpret this study. First, a chemiluminescence immunoassay was
305 used to assess vitamin D levels, this may lead to inconsistent results compared to other
306 techniques including competitive binding protein - CBP, radioimmunoassay - RIA liquid
307 chromatography - LC, UV detection with liquid chromatography and liquid chromatography
308 mass spectrometry LCMS or tandem mass spectrometry. Since most patients were
309 attended in the institution for the first time for COVID-19, historic vitamin D values were not
310 available to assess the effect of vitamin D dynamics on infection risk or outcomes.
311 Furthermore, given the disease course of COVID-19, severity profiles are highly
312 heterogeneous even amongst hospitalized patients, which may influence vitamin D values
313 on the basis of varying severity; control for this factor using propensity score matching was
314 carried out, however, there remains a possibility for residual confounding. Notably, these
315 results are from a COVID-19 reference center in Mexico City, this could reduce the
316 representativeness of the findings. Further evidence in other regions of Mexico to confirm
317 the role of vitamin D as a marker of disease severity and mortality in Mexicans with
318 COVID-19 is needed.

319 **Conclusions**

320 Vitamin D levels lower or equal to 12 ng/ml (30nmol/L) are independently associated with
321 COVID-19 mortality, even after adjusting for confounders (including measures of visceral
322 and total body fat). No association was confirmed between vitamin D levels and the need
323 for intubation. Vitamin D deficiency is more prevalent in women and patients with type 2
324 diabetes mellitus. Vitamin D supplementation may be considered in deficient patients, but
325 evidence of benefit is required from double blind randomized controlled trials.

326

327

328 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

329 **DATA AVAILABILITY:** Data is available from the corresponding author upon reasonable
330 request. Code for reproducibility of results available at:
331 https://github.com/oyaxbell/covid_metabolism

332 **FUNDING:** This research did not receive any specific grant from funding agencies in the
333 public, commercial, or not-for-profit sectors.

334 **ACKNOWLEDGMENTS**

335 All authors approved the submitted version. All the authors would like to thank the staff of
336 the Endocrinology and Metabolism Department for all their support. We are thankful to the
337 study volunteers for all their work and support throughout the realization of the study. AVV,
338 and NEAV are enrolled in the PECEM program at the Faculty of Medicine of UNAM; AVV
339 and NEAV are supported by CONACyT.

340 **CONTRIBUTIONS:** research idea and study design: RM, OYBC, CAAS; data acquisition:
341 RM, PEVC, NRP, MAJA, CIPC, BRE, JCVG, CAAS; data analysis/interpretation: OYBC,
342 RM, CAAS, NEAV, AVV; statistical analysis: OYBC, NEAV; manuscript drafting: RM,
343 OYBC, NEAV, AVV, CAAS; supervision or mentorship: RM, CAAS, APL, JSO. Each
344 author contributed important intellectual content during manuscript drafting or revision and
345 accepts accountability for the overall work by ensuring that questions pertaining to the
346 accuracy or integrity of any portion of the work are appropriately investigated and resolved.

347

348

349 **REFERENCES**

- 350 1. CDC, How COVID-19 Spreads. [https ://www.cdc.gov/coronavirus/2019-ncov/preve](https://www.cdc.gov/coronavirus/2019-ncov/preve)
351 [nt-getting-sick/how-covid -spreads.html](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html). 2020
- 352 2. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on
353 coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Mil Med*
354 *Res.* 2020;7(1):11
- 355 3. Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with
356 2019 novel coronavirus in Wuhan. *China Lancet Lond Engl.* 2020;395:497-506
- 357 4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
358 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
359 binding. *Lancet.* 2020; 395(10224):565– 574.
- 360 5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
361 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
362 observational study. *Lancet Respir Med.* 2020;8: 475-481.
- 363 6. Mahdavi A M. A brief review of interplay between vitamin D and angiotensin
364 converting enzyme 2: Implications for a potential treatment for COVID-19. *Rev Med*
365 *Viro.* 2020;1–6.
- 366 7. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among
367 free-living healthy young adults. *Am J Med.* 2002;112:659-662
- 368 8. Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E, Pittas
369 AG, Boland R, Ferrucci L, and Bikleet DD. Vitamin D: beyond bone. *Ann N Y Acad*
370 *Sci.* 2013;1287:45–58.
- 371 9. Zemb P, Bergman P, Camargo CA, Jr, Cavalier E, Cormier C, Courbebaisse M,
372 Hollis B, Joulia F, Minisola S, Pilz S, Pludowski P, Schmitt F, Zdrenghea M, and

- 373 Souberbielle JC. Vitamin D deficiency and the COVID-19 pandemic. *J Glob*
374 *Antimicrob Resist.* 2020 Sep; 22: 133–134
- 375 10. Tsiaras WG and Weinstock MA. Factors influencing vitamin D status. *Acta Derm*
376 *Venereol* 2011 Mar;91(2):115-24
- 377 11. Kim YA, Cho YJ. The association between visceral fat, subcutaneous fat and
378 serum 25-hydroxyvitamin D3 levels. *Obesity Medicine* 13 (2019) 29–33
- 379 12. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? *Lancet*
380 *Diabetes Endocrinol* 2020 Jul;8(7):570
- 381 13. Greiller CL and Martineau AR. Modulation of the Immune Response to Respiratory
382 Viruses by Vitamin D. *Nutrients* 2015, 7, 4240-4270
- 383 14. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-
384 Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ,
385 Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees
386 JR, Simpson S Jr, Stelmach I, Trilok Kumar G, Urashima M and Camargo CA Jr.
387 Vitamin D supplementation to prevent acute respiratory tract infections: systematic
388 review and meta-analysis of individual participant data *BMJ* 2017;356:i6583
- 389 15. D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, Keller
390 F, Cantù M. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with
391 Positive PCR for SARS CoV-2. *Nutrients.* 2020 May 9; 12:1359.
- 392 16. Meltzer DO, Best TJ, PhD, Zhang H, Vokes T, Arora V and Solway J. Association
393 of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test
394 Results. *JAMA Network Open.* 2020;3(9):e2019722
- 395 17. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Caulfield MJ,
396 Munroe PB, Harvey NC, Petersen SE. 2020 Greater risk of severe COVID-19 in

- 397 Black, Asian and Minority Ethnic populations is not explained by cardiometabolic,
398 socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326
399 cases from the UK Biobank. *J Public Health (Oxf)* Aug 18;42(3):451-460
- 400 18. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, and Merle U
401 (2020) Vitamin D deficiency and outcome of COVID 19 patients. *Nutrients* 12:2757.
402 <https://doi.org/10.3390/nu12092757>
- 403 19. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A,
404 González-Díaz A, Márquez-Salinas A, Fermín-Martínez CA, Naveja JJ,
405 Aguilar-Salinas CA. Predicting Mortality Due to SARS-CoV-2: A Mechanistic
406 Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. *J*
407 *Clin Endocrinol Metab.* 2020 Aug 1;105(8):dgaa346. doi:
408 10.1210/clinem/dgaa346.
- 409 20. Tzung-Dau Wang, et. al. 2009, Relations of Epicardial Adipose Tissue Measured
410 by Multidetector Computed Tomography to Components of the Metabolic
411 Syndrome Are Region-Specific and Independent of Anthropometric Indexes and
412 Intraabdominal Visceral Fat. *J Clin Endocrinol Metab*, 94(2):662– 669.
- 413 21. Michael T. Lu, MD. 2007, Reformatted Four-Chamber and Short-Axis Views of the
414 Heart Using Thin Section (≤ 2 mm) MDCT Images. *Acad Radiol* 2007; 14:1108–
415 1112
- 416 22. Angela Gallina Bertaso, 2013. Epicardial Fat: Definition, Measurements and
417 Systematic Review of Main Outcomes. DOI: 10.5935/abc.20130138
- 418 23. Evans RM and Lippman SM. Shining Light on the COVID-19 Pandemic: A Vitamin
419 D Receptor Checkpoint in Defense of Unregulated Wound Healing. *Cell*
420 *Metabolism*. 2020 Nov 3; 32(5):704-709

- 421 24. McCartney DM, O’Shea PM, Faul JL, Healy MJ, Byrne G, Griffin TP, Walsh JB,
422 Byrne DG and Kenny RA. Vitamin D and SARS-CoV-2 infection—evolution of
423 evidence supporting clinical practice and policy development. A position statement
424 from the Covit-D Consortium. Irish Journal of Medical Science (1971 -)
425 <https://doi.org/10.1007/s11845-020-02427-9>
- 426 25. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A,
427 Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N, Accili D, Binkley N,
428 Landry DW and Giustina A. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and
429 COVID-19. Eur J Endocrinol. 2020 Nov;183(5):R133-R147
- 430 26. Brown, R. 2020. Vitamin D deficiency: a factor in COVID-19, progression, severity
431 and mortality? – An urgent call for research. Mito Fit Preprint Arch., 1-29., (28.
432 Schwalfenberg, G. K. 2011. A review of the critical role of vitamin D deficiency.
433 Mol. Nutr. Food Res. 55, 96-108.28
- 434 27. Grant W, L. H. 2020. Evidence that Vitamin D Supplementation Could Reduce Risk
435 of Influenza and COVID-19 Infections and Deaths. Nutrients, 1-19
- 436 28. Wei Shan Hoong C, Huilin K, Cho S, Meyyur Aravamudan V and Hui Xian Lin J.
437 Are Adequate Vitamin D Levels Helpful in Fighting COVID-19? A Look at the
438 Evidence. Horm Metab Res. 2020 Nov; 52(11):775-783
- 439 29. E. Laird, J. R. 2020. Vitamin D and Inflammation: Potential Implications for Severity
440 of Covid-19. Irish Medical Journal, 81.
- 441 30. Jeffery, L. 2009. 1,25-dihydroxyvitamin D3 and interleukin-2 combine to inhibit T
442 cell production of inflammatory cytokines and promote development of regulatory T
443 cells expressing CTLA-4 and FoxP3. Journal of Immunology, 5458–5467.
- 444 31. Baeke, F., Takiishi, T. 2010. Vitamin D: modulator of the immune system. Current
445 Opinion in Pharmacology, 482–496.

- 446 32. Maghbooli Z, S. M. 2020. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at
447 least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-
448 19 infection. PLoS One, 1-13.
- 449 33. Carpagnano G, D. L. 2020. Vitamin D deficiency as a predictor of poor prognosis in
450 patients with acute respiratory failure due to COVID-19. Journal of Endocrinological
451 Investigation, 1-7
- 452 34. Weir, E. 2020. Does vitamin D deficiency increase the severity of COVID-19?
453 Clinical Medicine, 1-2.
- 454 35. Rodriguez Tort, A. 2020. La deficiencia de vitamina D es un factor de riesgo de
455 mortalidad en pacientes con COVID-19. Rev Sanid Milit Mex, 106-113.
- 456 36. Pan et al.2020. The impact of ethnicity on clinical outcomes in COVID-19: A
457 systematic review. EClinicalMedicine, 1-8.
- 458 37. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, Silva CBR,
459 Franco AS, Macedo MB, MD, Dalmolin HHH, Baggio J, Balbi GGM, Reis BZ,
460 Antonangelo L, Caparbo VF, Gualano B, Pereira RMR, MD. Effect of Vitamin D3
461 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe
462 COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial. doi:
463 10.1101/2020.11.16.20232397
- 464 38. Márquez-Salinas A, Fermín-Martínez CA, Antonio-Villa NE, Vargas-Vázquez A, C.
465 Guerra E, Campos-Muñoz A, Zavala-Romero L, Mehta R, Bahena-López JP, Ortiz-
466 Brizuela R, González-Lara MF, Roman-Montes CM, Martinez-Guerra BA, Ponce
467 de Leon A, Sifuentes-Osornio J, Gutiérrez-Robledo LM, Aguilar-Salinas CA, Bello-
468 Chavolla OY medRxiv 2020.11.03.20225375; doi: 10.1101/2020.11.03.20225375

469 TABLES

470 **Table 1.** Clinical characteristics, imaging findings and severity scores in patients with
 471 COVID-19, comparing cases with and without low vitamin D levels.

Parameter	Vitamin D	Vitamin D	P-value
	[>20 ng/mL] (n=300)	[≤20 ng/mL] (n=251)	
Age (years)	53.0 (±14.92)	51.0 (±12.60)	0.088
Male Sex (%)	219 (73%)	136 (54.2%)	<0.001
Low-Socioeconomic Status (%)	203 (67.66%)	172 (68.5%)	0.902
Critical outcome (%)	85 (28.3)	81 (32.3)	0.363
Intubation (%)	53 (17.6)	40 (15.9)	0.670
Mortality (%)	57 (19)	59 (23.5)	0.23
Arterial Hypertension (%)	83 (27.94%)	89 (35.9%)	0.058
Type 2 diabetes (%)	68 (22.9%)	78 (31.6%)	0.031
Time since diagnosis (years)	9.8 (±7.8)	9.20 (±7.5)	0.831
Obesity (%)	118 (39.9%)	111 (44.9%)	0.269
Smoking status (%)	15 (5.8%)	12 (5.8%)	0.789
CKD (%)	6 (2.0%)	12 (4.9%)	0.111

CVD (%)	6 (2.0%)	10 (4.0%)	0.258
Cirrhosis (%)	0 (0%)	3 (1.21%)	0.186
BMI (kg/m ²)	29.83 (±4.92)	30.32 (±6.56)	0.343
Respiratory Rate (rpm)	28.52 (±12.40)	28.31 (±9.11)	0.821
Heart Rate (bpm)	102.31 (±18.2)	101.85 (±18.5)	0.771
Systolic Arterial Pressure (mmHg)	120 (110-131)	123 (110-135)	0.264
Diastolic Arterial Pressure (mmHg)	76 (70-80)	74 (67-81)	0.322
Oxygen saturation (%)	82.65 (±11.4)	79.89 (±13.4)	0.010
C-reactive protein	14.93 (9.02- 23.20)	13.6 (6.37-21.76)	0.052*
Glucose levels (mg/dL)	149.7 (±85.73)	163.6 (±97.98)	0.0805*
HbA1c (%)	6.10 (5.8-7.05)	6.85 (6.0-9.6)	0.0040
Triglycerides (mg/dL)	149 (114-192)	140 (110-179)	0.2907
HDL-C (mg/dL)	32.7 (±15.25)	33.3 (±10.71)	0.9111
LDL-C (mg/dL)	95.9 (±57.38)	75.1 (±34.74)	0.2818
Total Cholesterol (mg/dL)	159.5 (±60.93)	135.7 (±44.23)	0.2658

Hemoglobin (%)	15.45 (1.85)	17.42 (22.99)	0.1794
Platelet Count ()	230.97 (90.89)	236.53 (103.83)	0.5089
Lymphocytes	8.91 (4.35)	9.16 (4.93)	0.5287
Neutrophils	6435.0 (4699.1)	6336.8 (5227.20)	0.8187
Serum Creatinine (mg/dL)	0.95 (0.79-1.15)	0.91 (0.74-1.16)	0.6451
Ferritin (mg/dl)	656.0 (323.3- 1138.7)	553.3 (284.7-959.7)	0.06174*
D-Dimer	629 (401-1049)	821 (454-1376)	0.00071
Protrombin	11.4 (10.8-12.4)	11.4 (10.6-12.5)	0.3642
Fibrinogen	697.0 (556.5- 854.5)	672 (482-789)	0.01406
BUN	18.1 (11.6)	20.7 (17.7)	0.0539*
AST	42.6 (30.5-62.5)	41.4 (30.1-64.7)	0.6787
ALT	35.9 (23.7-55-1)	33.50 (23.8-58.2)	0.6321
Albumin	3.8 (3.44-4.01)	3.6 (3.26-3.96)	0.0024
Lactate dehydrogenase	361 (291-466)	374 (278.5-498.5)	0.7565
CK	116 (64-236)	104.5 (55-225.3)	0.1976
Procalcitonin	0.270 (0.06-	0.32 (0.15-1.22)	0.2991

	0.57)		
Symptoms (n)	5 (3-5)	4 (3-5)	0.107
Comorbidities (n)	1 (0-1)	1 (0-2)	0.001
Time hospitalized (days)	6 (3-10)	6 (3-10)	0.995
CT findings			
Epicardial fat (%)	9.3 (7.3-11.7)	10 (8.2-12.2)	0.011
Pericardial fat (%)	185 (61.7)	145 (57.8)	0.407
Subthoracic fat (%)	15 (10-21)	17 (12-24)	0.010
Ground Glass Opacity (%)	297 (99)	248 (98)	0.710
Consolidations (%)	158 (53.6)	136 (54.2)	0.781
GGO + Consolidations (%)	158 (53.6)	136 (54.2)	0.721
Lobules affected	34 (11.3)	34 (11.3)	0.178
1	82 (32.7)	125 (41.7)	
2	132 (52.6)	140 (46.6)	
3			
Hepatic Steatosis (%)	99 (33)	90 (35.9)	0.539
Severity Scores			
NEWS (pts)	8 (6-9)	8 (7-9)	0.733
QSOFA (pts)	1 (1-1)	1 (1-1)	0.329

CURB-65 (pts)

1 (0-2)

1 (0-2)

0.347

472

473

474 **Table 2.** Multiple linear regression model to identify determinants of Vitamin D levels in
475 patients with COVID-19.

Model	Parameter	β- coefficient	95%CI	t	P- value
Vitamin D R ² =0.1091	Intercept	3.515	3.177-3.853	20.426	<0.001
	Male Sex	0.168	0.097 -0.238	4.668	<0.001
	Ultrasensitive troponin	-0.033	-0.063 - -0.002	-2.124	0.034
	D-dimer	-0.060	-0.100 - -0.020	-2.951	0.003
	C-reactive protein	0.065	0.026-0.103	3.265	0.001
	Epicardial fat	-0.126	-0.222 - -0.031	-2.599	0.010
	Type 2 diabetes	-0.072	-0.147 – 0.004	-1.871	0.062

476

477

478 **Table 3.** Cox proportional risk regression models to predict mortality related to COVID-19
 479 using Vitamin D levels adjusted for covariates. Model 1: Unadjusted, Model 2: Adjusted for
 480 age, gender, body-mass index (BMI) and C-reactive protein (CRP), Model 3: Model 2
 481 adjusted for chronic kidney disease (CKD), epicardial fat and type 2 diabetes (T2D).

Model	Parameter	β - coefficient	HR (95%CI)	P-value
Model 1 c-statistic=0.566	Vitamin D	-0.036	0.965 (0.942-0.988)	0.003
	Vitamin D	-0.043	0.938 (0.934-0.983)	0.001
Model 2 c-statistic=0.694	Age	0.037	1.037 (1.022-1.052)	<0.001
	Male gender	0.787	2.196 (1.373-3.512)	0.001
	BMI	0.038	1.039 (1.005-1.073)	0.024
	CRP	0.004	1.004 (1.002-1.007)	<0.001
Model 3 c-statistic=0.702	Vitamin D	-0.039	0.962 (0.935-0.989)	0.006
	CKD	0.301	0.749 (0.276-2.030)	0.570
	T2D	0.325	1.384 (0.882-2.170)	0.157
	Ultrasensitive cardiac troponin	0.170	1.185 (1.002-1.403)	0.048
	D-dimer	0.003	1.003 (0.804-1.252)	0.980

Oxygen saturation	-0.026	0.975 (0.960-0.990)	0.001
Epicardial fat thickness	0.669	1.952 (0.501-7.607)	0.335

482

483


484 **Table 4:** Causal mediation analyses predicting the effect of Vitamin D levels (E) mediated by elevated D-dimer, ultrasensitive cardiac
 485 troponins or low SpO2 (M) on severe COVID-19 and mortality (Y), adjusted by gender, age, BMI and epicardial fat.

486 **Abbreviations:** ACME: average causal mediation effects; ADE: average direct effects; SpO2: Oxygen saturation levels.

487

Outcome (Y)	Efector (E)	Mediator (M)	ACME (95%CI)	ADE (95%CI)	Total Effect (95%CI)	Proportion Mediated (95%CI)
COVID-19 Mortality	Vitamin D	D-dimer	-0.035 (-0.069,-0.010)	-0.144 (-0.164, -0.10)	-0.179 (-0.188,-0.050)	19.3% (9.5-77.0%)
		Ultrasentivie cardiac troponins	-0.047 (-0.085, -0.020)	-0.133 (-0.150, -0.020)	-0.181 (-0.183, -0.060)	26.2% (15.0-73.0%)
		SpO2	-0.037 (-0.066, -0.010)	-0.144 (-0.159, -0.030)	-0.181 (-0.186,-0.050)	20.3% (9.7-64.0%)

488 **FIGURE LEGENDS**




489

490 **Figure 1.** Boxplots comparing Vitamin D levels according to the need for invasive mechanical ventilation (IVM) or lethal COVID-19

491 stratified by gender (A-B) and by body-mass index categories (C-D).

492




493

494 **Figure 2.** Post-estimation simulation of Vitamin D levels to predict COVID-19 lethality, adjusted for age, sex, BMI, C-reactive protein,
495 epicardial fat, D-dimer, oxygen saturation, T2D, and CKD using Vitamin D cut-offs of <20ng/dL (A) and ≤ 12 ng/mL

496

497



498

499 **Figure 3.** Model-based causal mediation analyses to investigate the role of Vitamin D on COVID-19 mortality mediated by D-dimer

500 (A), ultrasensitive cardiac troponins (B)

501

502

503

504

505

506

507

508

509

510 **Supplementary Material**

511 **Table 1.** Clinical characteristics, imaging findings and severity scores in patients with COVID-19, comparing cases with and without
 512 severely low vitamin D levels (vitamin D deficiency).

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Age (years)	51.6 (13.7)	54.9 (13.9)	0.0865
Male Sex (%)	327 (66.2)	28 (49.2)	0.01626
Severe outcome (%)	142 (28.7)	24 (42.1)	0.0537
Intubation (%)	83 (16.8)	10 (17.4)	0.981
Letality (%)	95 (19.23)	21 (36.8)	0.0035
Low-Socioeconomic Status (%)	336 (68)	39 (68.3)	0.921
Arterial Hypertension (%)	150 (30.7)	22 (38.6)	0.293
Type 2 diabetes (%)	124 (25.5)	22 (38.6)	0.0512
Time since diagnosis (years)	9.1 (7.14)	11.6 (9.78)	0.297
Obesity (%)	204 (41.9)	25 (44.6)	0.8008
Smoking status (%)	26 (6.25)	1 (1.75)	0.921
CKD (%)	15 (3.10)	3 (5.26)	0.637
CVD (%)	14 (2.88)	2 (3.51)	0.921
Cirrhosis (%)	2 (0.41)	1 (1.75)	0.7256
BMI (kg/m ²)	30.0 (5.29)	30.5 (8.76)	0.7227
Respiratory Rate (rpm)	28.4 (11.4)	28.7 (6.9)	0.7946

Heart Rate (bpm)	102.5 (18.3)	98.8 (18.3)	0.1545
Systolic Arterial Pressure (mmHg)	122 (110-132)	120 (110-136)	0.3157
Diastolic Arterial Pressure (mmHg)	75 (70-80)	73 (66-80)	0.242
Oxygen saturation (%)	81.7 (12.2)	78.8 (13.8)	0.1302
C-reactive protein	14.7 (7.8-21.9)	12.8 (6.7-27.9)	0.8042

513

514

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Glucose levels (mg/dL)	152 (85.8)	185 (129.7)	0.0689
HbA1c (%)	6.3 (5.9-7.6)	8.0 (6.3-10.6)	0.00312
Triglycerides (mg/dL)	141 (111-183)	164 (118-237)	0.07487
HDL-C (mg/dL)	33 (13.4)	33 (7.78)	0.981
LDL-C (mg/dL)	84.7 (45.8)	80.3 (55.0)	0.887
Total Cholesterol (mg/dL)	147.7 (50.9)	135 (67.7)	0.7396
Hemoglobin	16.1 (12.3)	18.4 (28.9)	0.5584
Platelet Count	232.1 (95.5)	245.8 (108.9)	0.364
Leucocytes	8.96 (4.5)	9.62 (5.7)	0.4071

Neutrophils	6300.9 (4777.395)	7157.1 (6186.3)	0.3161
Serum Creatinine (mg/dL)	0.93 (0.77-1.15)	0.90 (0.75-1.19)	0.6636
Ferritin (mg/dl)	613 (287-1.069)	610 (389-984)	0.9173
D-Dimer	670 (413-1,178)	949 (567-1,803)	0.0025
Protrombin	11.4 (10.8-12.5)	11.4 (10.6-12.5)	0.4982
Fibrinogen	680 (526-820)	705 (464-896)	0.8438
BUN	18.8 (13.9)	23.9 (20.5)	0.0711
AST	41.9 (30.3-62.72)	42.6 (30.3-65.1)	0.6716
ALT	34.9 (23.9-56.8)	33.5 (22.3-53.6)	0.5808
Albumin	3.72 (3.38-4.00)	3.34 (2.93-3.77)	0.001
DHL	358 (283-476)	402 (316-521)	0.06721
CK	110 (61-229)	103 (55-250)	0.6239
Procalcitonina	0.27 (0.07-0.56)	3.045 (3.03-3.88)	0.034

515

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Symptoms (n)	4 (3-5)	4 (3-5)	0.162

Comorbid conditions (n)	1 (1-2)	2 (1-3)	0.042
Time hospitalized (days)	6 (3-10)	6 (3-8)	0.489
CT findings			
Epicardial fat (%)	9.7 (7.7-11.8)	10.2 (8.0-12.7)	0.105
Pericardial fat (%)	296 (59.4)	34 (59.6)	0.942
Subthoracic fat (%)	16 (11-22)	17 (12-25)	0.225
Ground Glass Opacity (%)	488 (98.8)	57 (100)	0.747
Consolidation (%)	258 (52.2)	36 (63.1)	0.162
GGO + Consolidation (%)	257 (52%)	36 (63.1)	0.154
Lobules affected	65 (13.1)	7 (12.3)	0.553
1	190 (38.5)	17 (29.8)	
2	239 (48.4)	33 (57.8)	
3			
Hepatic Steatosis (%)	172 (34.8)	17 (29.8)	0.545
Severity Scores			
NEWS (pts)	8 (6-9)	8 (7-9)	0.694
QSOFA (pts)	1 (1-2)	1 (1-2)	0.785
CURB-65 (pts)	1 (0-2)	1 (0-2)	0.341

516

517